Home Home Home Inbox Home Search

Event

Demonstration of Preclinical Efficacy in Pulmonary Fibrosis Models and of Clinical Safety, Tolerability, and Pharmacodynamic Effects of the First-in-Class Angiotensin AT2-Receptor Agonist Compound 21 (C21) [Board No. P1229]

Location: Board no. P1229
Session Type: Thematic Poster Session
Sunday
May
20
11:15 AM
1:00 PM

Speaker(s)/Author(s)

Anna Wiksten

PhD
StatFinn

Lena Lindblad

PhD
Vicore Pharma

Bjoern Dahloef

MD PhD
Sahlgrenska University

Mika Scheinin

MD PhD
University of Turku

Colin Sumners

PhD
University of Florida

Pasi Korhonen

PhD
StatFinn

Anandharajan Rathinasabapathy

PhD
Vanderbilt University

Johanna Graens

PhD
Vicore Pharma

Petri Vainio

PhD
University of Turku

Vinayak Shenoy

PhD
California Health Sciences University

Erin Bruce

PhD
University of Florida

Per Jansson

DDS
Vicore Pharma

Ulrike Muscha. Steckelings

MD PhD
Vicore Pharma

Thomas Unger

MD PhD
CARIM - Maastricht University

Michael Katovich

PhD
University of Florida

View Abstract

Demonstration of Preclinical Efficacy in Pulmonary Fibrosis Models and of Clinical Safety, Tolerability, and Pharmacodynamic Effects of the First-in-Class Angiotensin AT2-Receptor Agonist Compound 21 (C21)

Parent Sessions

  • A42 - ILD SCIENTIFIC ABSTRACTS: TREATMENT AND ACUTE EXACERBATION...
    05-20-2018 9:15 AM - 4:15 PM
    • Home Home Home Inbox Home Search